Hans Olav Melberg
- Researcher / Associate Professor; PhD
- +47-22 84 50 31
Health economics, economic evaluation and econometrics
A nationwide registry study on heart failure in Norway from 2008 to 2018: variations in lookback period affect incidence estimates
BMC Cardiovasc Disord, 22 (1), 88
First-line biologic treatment of inflammatory bowel disease during the first 12 months after diagnosis from 2010 to 2016: a Norwegian nationwide registry study
Scand J Gastroenterol, 56 (10), 1163-1168
What are determinants of utilisation of pharmaceutical anticancer treatment during the last year of life in Norway? A retrospective registry study
BMJ Open, 11 (9), e050564
Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study
Therap Adv Gastroenterol, 14, 17562848211021760
Using fees to reduce bed-blocking: a game between hospitals and long-term care providers
Eur J Health Econ, 22 (6), 931-949
Incidence and Prevalence of Inflammatory Bowel Disease in Norway and the Impact of Different Case Definitions: A Nationwide Registry Study
Clin Epidemiol, 13, 287-294
Cost-Effectiveness of Noninvasive Screening for Alcohol-Related Liver Fibrosis
Hepatology, 71 (6), 2093-2104
Incidence, prevalence, and mortality of heart failure: a nationwide registry study from 2013 to 2016
ESC Heart Fail, 7 (4), 1917-1926
The Cost-Effectiveness of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer in Norway
MDM Policy Pract, 4 (1), 2381468318821103
Value in Health: How It Is Defined and Used in Priority Setting and Pricing in Norway
Healthc Pap, 18 (3), 22-28
Cost-utility of allogeneic hematopoietic stem cell transplantation in Norway
Bone Marrow Transplant, 53 (5), 657-660
Cost analysis of mobile radiography services for nursing home residents in Southeast Norway
J Eval Clin Pract, 25 (2), 275-281
Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study
Scand J Gastroenterol, 53 (8), 952-957
Did adolescents in Norway respond to the elimination of copayments for general practitioner services?
Health Econ, 27 (7), 1120-1130
Comparison of Site of Death, Health Care Utilization, and Hospital Expenditures for Patients Dying With Cancer in 7 Developed Countries
JAMA, 315 (3), 272-83
Governance of addictions
Tidsskr. Nor. Laegeforen., 136 (9), 847
Did hospitals respond to changes in weights of Diagnosis Related Groups in Norway between 2006 and 2013?
Health Policy, 120 (9), 992-1000
A new proposal for priority setting in Norway: Open and fair
Health Policy, 120 (3), 246-51
The effects of introducing an electronic prescription system with no copayments
Health Econ Rev, 5 (1), 56
European Regional Differences in All-Cause Mortality and Length of Stay for Patients with Hip Fracture
Health Econ, 24 Suppl 2, 53-64
Are healthcare expenditures increasing faster for the elderly than the rest of the population?
Expert Rev Pharmacoecon Outcomes Res, 14 (5), 581-3
Norwegian physicians' knowledge of the prices of pharmaceuticals: a survey
PLoS One, 8 (9), e75218
Addiction: choice or compulsion?
Front Psychiatry, 4, 77
[Unnecessary confusion about health expenses]
Tidsskr Nor Laegeforen, 133 (9), 935
The economic theory of history: an introduction
Tidsskr. Samfunnsforsk., 54 (3), 396-399
Hospital expenses towards the end of life
Tidsskr Nor Laegeforen, 133 (8), 841-4
Addiction and Responsibility: A Survey of Opinions
Inquiry-Interdiscip. J. Philos., 56 (5), 558-570
Social cost of alcohol: Not always useless even if subjective?
Nord. Stud. Alcohol Drugs, 29 (4), 355-357
Study-design selection criteria in systematic reviews of effectiveness of health systems interventions and reforms: A meta-review
Health Policy, 104 (3), 206-14
Measuring the harm of illicit drug use on friends and family
Nord. Stud. Alcohol Drugs, 28 (2), 105-121
Acceptance of unsupported claims about reality: a blind spot in economics
J. Econ. Methodol., 18 (1), 29-52
[What do doctors think an MR examination costs?]
Tidsskr Nor Laegeforen, 130 (6), 598-600
Ineligibility and refusal to participate in randomised trials of treatments for drug dependence
Drug Alcohol Rev, 29 (2), 193-201
Is cannabis a gateway to hard drugs?
Empir. Econ., 38 (3), 583-603
Do smoke-free laws affect revenues in pubs and restaurants?
Eur J Health Econ, 13 (1), 93-9
Sequential patterns of drug use initiation - Can we believe in the gateway theory?
B E J. Econ. Anal. Policy, 8 (2), 1
Becker's rational addiction theory: An empirical test with price elasticities for distilled spirits in Denmark 1911-31
Addiction, 101 (10), 1444-50
The spread of drug use: epidemic models or social interaction?
Adv Health Econ Health Serv Res, 16, 173-99
Hvilken nytte, for hvem og til hvilken kostnad?: en prospektiv studie av stoffmisbrukere i behandling
In SIRUS-rapport, SIRUS, Oslo, Nr. 4/2003, 166 s.